儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

CAR-NK 细胞中 IL-10 的耗竭增强肿瘤微环境的重编程并改善治疗效果

Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.

胶质瘤中的 NK 细胞功能障碍：从免疫逃逸到免疫治疗

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.

靶向 ErbB2/HER2 的 CAR-NK 细胞在重现肿瘤进展的类器官模型中清除乳腺癌细胞

ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.

CAR-NK 细胞疗法联合免疫检查点抑制在胶质母细胞瘤中诱导 NKT 细胞应答

CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.

该联合治疗逆转了免疫抑制性肿瘤微环境，T 细胞和 NKT 细胞浸润增加。

针对多形性胶质母细胞瘤的 NK 细胞免疫治疗潜在分子靶点

Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.

双靶向胶质母细胞瘤细胞的双特异性杀伤细胞衔接器靶向 EGFR 和 ErbB2（HER2）促进 NKG2D-CAR 工程化 NK 细胞的有效清除

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D

复发性胶质母细胞瘤患者颅内注射经 HER2 靶向嵌合抗原受体工程化的 NK 细胞

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.

颅内注射 HER2 靶向 CAR-NK 细胞在复发性 GB 患者中是可行且安全的。1 108 个 NK-92/5.28.z 细胞被确定为后续扩展队列重复局部注射 CAR-NK 细胞的最大可行剂量。

AAV 介导的检查点抑制剂基因转移联合 HER2 靶向 CAR-NK 细胞作为胶质母细胞瘤的实验性治疗

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.

2009 至 2021 年 CAR-T 细胞的文献计量学与知识图谱分析

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。